Story code: ST-001566
Part 3: The Quota
Maya stared at the cheap plastic burner phone resting on the flattened cardboard. The oppressive afternoon heat radiated off the concrete, baking the smell of exhaust into her clothes. Her own phone lay in pieces a few feet away, crushed under the polished leather shoe of the man who had just handed her a death sentence for her parents’ financial future.
She picked up the prepaid device. The screen glowed with a generic blue background. It had a basic, clunky web browser. She desperately needed to warn her mother about the county sheriff’s looming eviction. Her fingers trembled as she typed her email provider’s URL into the browser, fighting the miniature keyboard to log in.
The inbox loaded slowly over a weak cellular connection. At the top, bolded and unread, sat a new message from the exact same anonymous address that had donated two hundred dollars to her GoFundMe five days ago. The subject line read: *URGENT – APEX MEDICAL – JULIAN VANCE*.
Maya tapped the screen. The text was brief: *They are trying to buy your silence today. Do not sign the NDA. Here is exactly why the treatments failed.*
Below the text was a PDF attachment titled *Q3_Internal_Pricing_Memo.pdf*.
Maya downloaded the file. Her eyes scanned the dense corporate letterhead, landing on an internal email authored by Julian Vance, VP of Regional Acquisitions. She read the first paragraph, and the breath violently hitched in her throat.
It wasn’t a medical document. It was a profit quota mandate. Apex hadn’t just administered a failed experimental treatment to her father; they had deliberately inflated the dosage schedules across the entire trial. The email explicitly directed regional clinic directors to increase the frequency of neural-pathway sessions by forty percent solely to accelerate the depletion of patients’ equity-release funds before the fiscal quarter ended.
A bullet point near the bottom of the page made her stomach twist. *Note: Accelerated dosage schedules carry a 92% probability of inducing permanent motor-function degradation (severe tremors). Adjust liability waivers accordingly.*
They knew. They had artificially inflated her father’s dosage schedule to drain his home equity faster, knowingly destroying his nervous system to hit a quarterly profit target.
The whistleblower’s email had a second line. *Vance is hosting a catered recruitment lunch for the regional oncology board right now at The Sterling Steakhouse on 4th. He is expanding the equity-release model to cancer patients. Stop him.*
Maya looked at the digital clock on the burner phone. It was 2:45 PM. The Sterling Steakhouse was only three blocks away. She looked down at the thick white envelope containing the non-disclosure agreement. She thought of her father’s fiercely shaking hands, his fractured memory, the absolute theft of his dignity-all of it coldly quantified into a $412,000 fraudulent debt.
She didn’t walk. She ran.
The heavy oak doors of The Sterling Steakhouse offered a blast of frigid, over-conditioned air as Maya pushed her way inside. The host stand was empty for a fleeting second, the maître d’ distracted by a busboy. Maya bypassed the dim, mahogany-paneled main dining room, scanning the brass placards beside the heavy sliding doors at the back of the restaurant.
She found it. *Private Dining – Apex Medical Solutions*.
Maya shoved the heavy wooden door open. The ambient noise of the restaurant vanished, replaced by the clinking of expensive crystal and the low, self-important murmur of a dozen medical professionals. The long, polished table was lined with men and women in tailored clothing, picking at dry-aged steaks and sipping red wine.
At the head of the table stood the man in the charcoal suit. Julian Vance. His jacket was finally unbuttoned, his posture relaxed as he held up a glass of Cabernet, projecting a holographic slide from his laptop onto the far wall.
“The beauty of the equity-release model,” Julian was saying, his smooth baritone commanding the room, “is that it entirely removes the insurance ceiling. When you partner your oncology clinics with Apex, your cancer patients’ home equity becomes direct, frictionless capital for cutting-edge-”
“Because you cook the dosage schedules to drain their accounts!” Maya shouted, her voice echoing sharply off the acoustic ceiling tiles.
The room went dead silent. A dozen oncologists turned in their leather chairs, staring at the disheveled, sweat-drenched woman standing in the doorway clutching a cheap plastic cell phone and a crumpled legal envelope.
Julian’s polite smile vanished instantly. His eyes locked onto her, flashing with a sudden, dangerous panic. He set his wine glass down with a sharp clink. “Excuse me, this is a private corporate event. You need to leave immediately.” He gestured toward the door, taking a step toward her.
Maya stood her ground, her thumb swiping down the glowing screen of the burner phone. She raised her voice, projecting it over his interruption.
“I have an internal memo sent by Julian Vance to the Apex billing department,” Maya announced, her hands shaking so hard she had to grip the phone with both palms to read it. “Subject: Q3 Revenue Optimization.”
“Security!” Julian barked, pointing toward the hallway. “Get her out of here!”
“Quote,” Maya read, pushing her volume to a near-scream to be heard over Julian’s approaching footsteps. “‘Direct all partnered clinics to increase session frequency by forty percent. Do not wait for standard diagnostic intervals. Maximum equity extraction must be achieved before the end of the fiscal year.'”
A murmur rippled through the seated doctors. Several of them sat up straighter, trading uneasy glances. The head of a prominent local clinic lowered his steak knife, staring hard at Julian.
“Stop talking,” Julian hissed, closing the distance. He reached out to snatch the phone from her hands, dropping the polite facade entirely.
Maya stepped back, dodging his grasping hand, and kept reading. “‘Note: Accelerated dosage schedules carry a ninety-two percent probability of inducing permanent motor-function degradation. Ensure all new equity-release patients sign the updated liability waivers.'”
The heavy silence that followed was suffocating. The oncologists, who had been nodding along to Julian’s pitch moments before, were now staring at him in absolute horror. Prescribing unnecessary treatments was a severe violation of medical ethics; intentionally inflating dosages to the point of permanent physical damage just to drain a patient’s mortgage was criminal fraud.
“Is that true, Julian?” asked an older woman near the center of the table, her voice dangerously quiet. She pushed her half-empty wine glass away. “Are you artificially inflating the dosage schedules on your trials to drain their equity accounts?”
Julian froze. His hand hung mid-air, inches from Maya’s shoulder. The smooth, predatory confidence that had dominated the sidewalk earlier had completely evaporated. He looked at the table of oncologists, his jaw working silently as he tried to formulate a response. His eyes darted from the glaring clinicians back to Maya, the pristine wool suit suddenly looking like a trap he couldn’t escape.